Sight Sciences Inc (SGHT) Stock Price, Quote & News

Company Profile

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients wi...

Industry: Medical Devices

Sector: Healthcare

Phone: 877 266 1144

Fax: 650 352 4401

Website: www.sightsciences.com

Address:

4040 Campbell Avenue, Suite 100, Menlo Park, United States

Rvsty Sep. 11 at 7:44 PM

$SGHT 👀

0 · Reply

YouOnlyLiveTwice Sep. 9 at 1:11 PM

$SGHT $MMA $SOS $CUPR $TECK Here the spammers Blocked

0 · Reply

OpenOutcrier Sep. 9 at 12:34 PM

$SGHT (+2.4% pre) Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments https://ooc.bz/l/76603

0 · Reply

DARKP00L Sep. 9 at 12:03 PM

$SGHT 07:56 on Sep. 09 2025 SGHT stock has given up its prior gain. ight Sciences shares were trading higher after UnitedHealthcare expanded coverage to include the company's OMNI Surgical System for glaucoma treatments. #tradeideas

0 · Reply

DARKP00L Sep. 9 at 12:00 PM

$SGHT 07:08 on Sep. 09 2025 ight Sciences shares are trading higher after UnitedHealthcare expanded coverage to include the company's OMNI Surgical System for glaucoma treatments. #tradeideas

0 · Reply

DARKP00L Sep. 9 at 12:00 PM

$SGHT 07:07 on Sep. 09 2025 Sight Sciences' OMNI Surgical System To Be Included In UnitedHealthcare's Expanded Coverage Of Glaucoma Surgical Treatments #tradeideas

0 · Reply

caprihunter Sep. 9 at 11:28 AM

$SGHT Sight Sciences (NASDAQ:SGHT) announced that UnitedHealthcare (UHC) will include its OMNI® Surgical System in its expanded coverage policy for glaucoma surgical treatments, effective October 1, 2025. The coverage applies to UHC's commercial and individual exchange benefit plans, reaching approximately 30 million of UHC's over 50 million total covered lives. The policy covers procedures including goniotomy, trabeculotomy, canaloplasty, and combined procedures for adults with mild to moderate open-angle glaucoma. The FDA-cleared OMNI Surgical System is indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open angle glaucoma, and can be performed before, during, or after cataract surgery... $MMA $SOS $CUPR $TECK

0 · Reply

caprihunter Sep. 9 at 11:14 AM

0 · Reply

TheBullishTrade Sep. 9 at 11:10 AM

$SGHT Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments Tuesday, 9th September at 7:05 am MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and combined canaloplasty (ab interno) and trabeculotomy procedures for adults (age 19 years or more), when deemed medically necessary for treating mild to moderate open-angle glaucoma (OAG) and cataract in adults currently being treated with ocular hypotensive medication.

0 · Reply

NVDAMillionaire Sep. 4 at 6:41 AM

$SGHT Excellent article that nails exactly where SGHT stands right now. So if you want to update your SGHT knowledge or get acquainted with SGHT, this is a must read. https://beyondspx.com/quote/SGHT/sight-sciences-interventional-vision-strategic-resilience-and-the-path-to-profitability-nasdaq-sght#analysis

0 · Reply

Sight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 7:05 AM EDT - 5 days ago

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

Sep 2, 2025, 4:05 PM EDT - 12 days ago

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

Aug 26, 2025, 4:05 PM EDT - 19 days ago

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Aug 8, 2025, 6:48 AM EDT - 5 weeks ago

Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 weeks ago

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Jul 30, 2025, 7:00 AM EDT - 6 weeks ago

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

Jul 29, 2025, 7:00 AM EDT - 6 weeks ago

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

Jul 24, 2025, 4:05 PM EDT - 7 weeks ago

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

May 14, 2025, 4:05 PM EDT - 4 months ago

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

May 11, 2025, 1:26 AM EDT - 4 months ago

Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 4 months ago

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

Apr 24, 2025, 4:05 PM EDT - 5 months ago

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 23, 2025, 4:05 PM EDT - 5 months ago

Sight Sciences Announces the Release of its Sustainability Report

Apr 22, 2025, 4:05 PM EDT - 5 months ago

Sight Sciences Appoints Gary Burbach to its Board of Directors

Apr 21, 2025, 4:05 PM EDT - 5 months ago

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

Mar 25, 2025, 4:05 PM EDT - 6 months ago

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Mar 5, 2025, 10:06 PM EST - 6 months ago

Sight Sciences, Inc. (SGHT) Q4 2024 Earnings Conference Call Transcript

Mar 5, 2025, 4:05 PM EST - 6 months ago

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

Feb 24, 2025, 4:05 PM EST - 7 months ago

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

Feb 19, 2025, 4:05 PM EST - 7 months ago

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

Feb 13, 2025, 4:05 PM EST - 7 months ago

Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day

Dec 19, 2024, 4:05 PM EST - 9 months ago

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

Nov 19, 2024, 4:05 PM EST - 10 months ago

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 9, 2024, 1:32 PM EST - 11 months ago

Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:58 AM EST - 11 months ago

Top 3 Health Care Stocks You'll Regret Missing In November

CMPS PACS

Oct 17, 2024, 4:05 PM EDT - 11 months ago

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

Oct 14, 2024, 4:05 PM EDT - 11 months ago

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

Aug 3, 2024, 3:12 AM EDT - 1 year ago

Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

Jun 10, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences Announces the Release of its First Sustainability Report

May 28, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

May 28, 2024, 8:30 AM EDT - 1 year ago

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

May 5, 2024, 1:58 AM EDT - 1 year ago

Sight Sciences, Inc. (SGHT) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Apr 29, 2024, 8:05 AM EDT - 1 year ago

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

Apr 18, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

Apr 10, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2

$Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting$

Apr 2, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Mar 26, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

Mar 7, 2024, 10:56 PM EST - 1 year ago

Sight Sciences, Inc. (SGHT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

Feb 22, 2024, 4:05 PM EST - 1 year ago

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

Feb 14, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

Jan 23, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital

Jan 8, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Dec 28, 2023, 9:15 AM EST - 1 year ago

Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors

Dec 18, 2023, 4:05 PM EST - 1 year ago

Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease

Dec 8, 2023, 8:05 AM EST - 1 year ago

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Nov 11, 2023, 12:38 PM EST - 2 years ago

Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript

Rvsty Sep. 11 at 7:44 PM

$SGHT 👀

0 · Reply

YouOnlyLiveTwice Sep. 9 at 1:11 PM

$SGHT $MMA $SOS $CUPR $TECK Here the spammers Blocked

0 · Reply

OpenOutcrier Sep. 9 at 12:34 PM

$SGHT (+2.4% pre) Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments https://ooc.bz/l/76603

0 · Reply

DARKP00L Sep. 9 at 12:03 PM

0 · Reply

DARKP00L Sep. 9 at 12:00 PM

$SGHT 07:08 on Sep. 09 2025 ight Sciences shares are trading higher after UnitedHealthcare expanded coverage to include the company's OMNI Surgical System for glaucoma treatments. #tradeideas

0 · Reply

DARKP00L Sep. 9 at 12:00 PM

$SGHT 07:07 on Sep. 09 2025 Sight Sciences' OMNI Surgical System To Be Included In UnitedHealthcare's Expanded Coverage Of Glaucoma Surgical Treatments #tradeideas

0 · Reply

caprihunter Sep. 9 at 11:28 AM

0 · Reply

caprihunter Sep. 9 at 11:14 AM

0 · Reply

TheBullishTrade Sep. 9 at 11:10 AM

0 · Reply

NVDAMillionaire Sep. 4 at 6:41 AM

0 · Reply

lawson Aug. 30 at 7:25 PM

$SGHT https://ebs.publicnow.com/view/34C380A8A1824BDA89FAE7587D6144361745D9B8

0 · Reply

JarvisFlow Aug. 28 at 4:45 PM

Needham has updated their rating for Sight Sciences ( $SGHT ) to Hold.

0 · Reply

Doozio Aug. 22 at 4:24 PM

😂🍿. No “setups”. No $SGHT 🐒🍌🧠⏰♾️

0 · Reply

JarvisFlow Aug. 21 at 6:14 PM

Citigroup updates rating for Sight Sciences ( $SGHT ) to Neutral, target set at 3.6 → 4.5.

0 · Reply

JarvisFlow Aug. 8 at 10:30 PM

Lake Street has updated their rating for Sight Sciences ( $SGHT ) to Buy with a price target of 5.

0 · Reply

lawson Aug. 5 at 12:12 PM

$SGHT Management has failed investors. How long can this company exist with only 1 product in distribution? The eye heaters? Years away from distribution?

1 · Reply

JarvisFlow Jun. 18 at 3:22 PM

Piper Sandler has updated their rating for Sight Sciences ( $SGHT ) to Neutral with a price target of 4.

0 · Reply

AZOZ Jun. 4 at 11:07 AM

$SGHT insider keep loading Stay tuned!

0 · Reply

PenkeTrading Jun. 4 at 9:19 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Sight Sciences Inc. Is that bullish or bearish? $SGHT #RsiOverbought #NASDAQ

0 · Reply

swingingtech Jun. 4 at 3:36 AM

$SGHT https://wallstreetwaves.com/director-acquires-25230-shares-of-sght-in-insider-purchase/

0 · Reply

AZOZ May. 30 at 12:35 PM

$SGHT $VFF insider love it right now

0 · Reply

AlertsAndNews May. 30 at 2:51 AM

$SGHT Insider buy here: Staffan Encrantz (Director, 10%+ owner) buys 128,189 shares at an average price of $3.52.

1 · Reply

Market Cap	181.19M
Revenue (ttm)	79.87M
Net Income (ttm)	-51.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-64.49%
Debt to Equity Ratio	0.57

Volume	97,000
Avg Vol	121,380
Day's Range	N/A - N/A
Shares Out	52.37M
Stochastic %K	13%
Beta	2.46
Analysts	Sell
Price Target	$4.42